Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.400
+0.010 (0.42%)
Sep 16, 2025, 12:58 PM EDT - Market open

Annovis Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
5.826.76.2496.063.59
Upgrade
Research & Development
17.862038.7916.528.483.05
Upgrade
Operating Expenses
23.6826.6945.0425.5114.546.64
Upgrade
Operating Income
-23.68-26.69-45.04-25.51-14.54-6.64
Upgrade
Interest & Investment Income
0.640.330.670.180.010.05
Upgrade
Other Non Operating Income (Expenses)
-7.221.77-11.84-0.041.13
Upgrade
Pretax Income
-30.26-24.59-56.2-25.33-14.49-5.46
Upgrade
Net Income
-30.26-24.59-56.2-25.33-14.49-5.46
Upgrade
Net Income to Common
-30.26-24.59-56.2-25.33-14.49-5.46
Upgrade
Shares Outstanding (Basic)
16129886
Upgrade
Shares Outstanding (Diluted)
16129886
Upgrade
Shares Change (YoY)
55.91%35.60%10.55%7.03%20.88%2132.36%
Upgrade
EPS (Basic)
-1.90-2.02-6.23-3.10-1.90-0.87
Upgrade
EPS (Diluted)
-1.90-2.31-6.23-3.10-1.90-0.87
Upgrade
EBIT
-23.68-26.69-45.04-25.51-14.54-6.64
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q